OrthoPediatrics and iotaMotion Partner Receive FDA Clearance
- FDA Clearance Expansion: iotaMotion's iotaSOFT® Insertion System has received FDA 510(k) clearance for use in children aged four and older, significantly broadening access to robotic-assisted cochlear implantation and expected to enhance OrthoPediatrics' market share in the pediatric ENT sector.
- Deepening Strategic Partnership: The collaboration between OrthoPediatrics and iotaMotion aims to integrate advanced robotic technology into pediatrics, improving the efficiency and consistency of cochlear implant surgeries, thereby solidifying its leadership position in pediatric healthcare.
- First Adopting Hospital: Cincinnati Children's Hospital becomes the first dedicated pediatric center to adopt the iotaSOFT Insertion System, joining over 35 leading cochlear implant centers in the U.S., marking widespread recognition of this technology in pediatrics and likely encouraging further hospital adoption.
- Broad Market Prospects: OrthoPediatrics plans to leverage this technology to expand its impact in pediatric care, supported by a capital-light business model and diverse revenue streams, addressing unmet pediatric needs effectively.
Trade with 70% Backtested Accuracy
Analyst Views on KIDS
About KIDS
About the author
OrthoPediatrics Reports Strong Q4 2025 Earnings with Positive Cash Flow
- Significant Revenue Growth: OrthoPediatrics reported worldwide revenue of $61.6 million for Q4 2025, reflecting a 17% year-over-year increase, with U.S. revenue at $48.6 million and international revenue at $13.0 million, demonstrating strong performance across trauma, deformity, and scoliosis segments, thereby solidifying its market position.
- First Positive Free Cash Flow: The company achieved $10 million in free cash flow during Q4 2025, marking its first quarter of positive cash flow in history, which indicates a significant improvement in operational efficiency and provides funding support for future investments and expansions.
- Optimistic 2026 Outlook: Management reiterated its revenue guidance for 2026 at $262 million to $266 million, projecting an annual growth rate of 11% to 13%, while also expecting approximately $25 million in adjusted EBITDA, reflecting confidence in sustained profitability and growth.
- Launch of Innovation Cycle: The company commenced what it believes to be the most substantial series of product launches in its history in 2025, including the 3P Hip and VerteGlide, which is expected to initiate a multi-year super cycle of product innovation, laying a foundation for future growth and expanding market share.
OrthoPediatrics Q4 Earnings Report Analysis
- Earnings Performance: OrthoPediatrics reported a Q4 GAAP EPS of -$0.43, missing expectations by $0.09, indicating challenges in profitability that could affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $61.6 million, a 16.9% year-over-year increase, surpassing market expectations by $0.33 million, demonstrating sustained demand in the pediatric orthopedic market and enhancing future growth potential.
- Future Outlook: OrthoPediatrics projects FY25 revenue of $236.1 million, reflecting a positive outlook for future markets, although current profitability issues suggest a need for improvement in earnings management.
- Market Reaction: Despite strong revenue growth, the decline in EPS may lead to negative short-term reactions from the market, prompting investors to monitor future measures for profitability improvement.
OrthoPediatrics and iotaMotion Partner Receive FDA Clearance
- FDA Clearance Expansion: iotaMotion's iotaSOFT® Insertion System has received FDA 510(k) clearance for use in children aged four and older, significantly broadening access to robotic-assisted cochlear implantation and expected to enhance OrthoPediatrics' market share in the pediatric ENT sector.
- Deepening Strategic Partnership: The collaboration between OrthoPediatrics and iotaMotion aims to integrate advanced robotic technology into pediatrics, improving the efficiency and consistency of cochlear implant surgeries, thereby solidifying its leadership position in pediatric healthcare.
- First Adopting Hospital: Cincinnati Children's Hospital becomes the first dedicated pediatric center to adopt the iotaSOFT Insertion System, joining over 35 leading cochlear implant centers in the U.S., marking widespread recognition of this technology in pediatrics and likely encouraging further hospital adoption.
- Broad Market Prospects: OrthoPediatrics plans to leverage this technology to expand its impact in pediatric care, supported by a capital-light business model and diverse revenue streams, addressing unmet pediatric needs effectively.
OrthoPediatrics Corp. Enhances Specialty Bracing Line with Launch of Two New Products
New Product Launches: OrthoPediatrics Corp. has expanded its OrthoPediatrics Specialty Bracing portfolio with the introduction of the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems, aimed at treating Developmental Dysplasia of the Hip (DDH) in children aged three years and younger.
Collaboration with Experts: The new products were developed in collaboration with leading pediatric hip specialists, enhancing treatment options for patients and their families.
Commitment to Pediatric Care: Joe Hauser, President of the Specialty Bracing division, emphasized the company's focus on organic product development and its commitment to improving pediatric orthopedic care through innovative solutions.
Comprehensive Product Offering: Founded in 2006, OrthoPediatrics markets over 85 products across various pediatric orthopedic categories, including trauma, deformity, scoliosis, and sports medicine, serving both the U.S. and international markets.
What Factors Might Influence the OrthoPediatrics Narrative Following Analyst Updates?
Analyst Price Target Changes: OrthoPediatrics' consensus analyst price target has been lowered from $26.29 to $24.14, reflecting a cautious outlook amid mixed research commentary and short-term challenges.
Bullish Analyst Sentiment: Despite the lowered price targets, several firms maintain positive ratings, emphasizing confidence in the company's core business and long-term prospects, particularly in high-margin product lines.
Bearish Analyst Concerns: Some analysts express caution, citing near-term headwinds and lower guidance, with notable reductions in price targets and concerns over revenue visibility impacting future growth expectations.
Company Developments: OrthoPediatrics announced an intangible asset impairment of $2.27 million, received FDA approval for a new system, and revised its 2025 revenue guidance downward, while also reporting improved net profit margins.
Understanding OrthoPediatrics: Key Takeaways from 9 Analyst Evaluations
Analyst Ratings Overview: OrthoPediatrics has received mixed ratings from analysts, with 6 bullish, 3 somewhat bullish, and no bearish ratings in the last 30 days, reflecting a shift in sentiment compared to previous months.
Price Target Adjustments: Analysts have lowered their 12-month price targets for OrthoPediatrics, with an average target now at $27.44, down from $36.44, indicating a decrease in expected stock performance.
Financial Performance Metrics: The company has shown a revenue growth rate of approximately 15.68% and maintains a net margin of -11.64%, outperforming industry standards in terms of financial performance.
Debt Management and Ratios: OrthoPediatrics has a debt-to-equity ratio of 0.27, which is below industry norms, suggesting a solid financial structure and effective management of shareholder equity.
OrthoPediatrics Reports Strong Q4 2025 Earnings with Positive Cash Flow
- Significant Revenue Growth: OrthoPediatrics reported worldwide revenue of $61.6 million for Q4 2025, reflecting a 17% year-over-year increase, with U.S. revenue at $48.6 million and international revenue at $13.0 million, demonstrating strong performance across trauma, deformity, and scoliosis segments, thereby solidifying its market position.
- First Positive Free Cash Flow: The company achieved $10 million in free cash flow during Q4 2025, marking its first quarter of positive cash flow in history, which indicates a significant improvement in operational efficiency and provides funding support for future investments and expansions.
- Optimistic 2026 Outlook: Management reiterated its revenue guidance for 2026 at $262 million to $266 million, projecting an annual growth rate of 11% to 13%, while also expecting approximately $25 million in adjusted EBITDA, reflecting confidence in sustained profitability and growth.
- Launch of Innovation Cycle: The company commenced what it believes to be the most substantial series of product launches in its history in 2025, including the 3P Hip and VerteGlide, which is expected to initiate a multi-year super cycle of product innovation, laying a foundation for future growth and expanding market share.
OrthoPediatrics Q4 Earnings Report Analysis
- Earnings Performance: OrthoPediatrics reported a Q4 GAAP EPS of -$0.43, missing expectations by $0.09, indicating challenges in profitability that could affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $61.6 million, a 16.9% year-over-year increase, surpassing market expectations by $0.33 million, demonstrating sustained demand in the pediatric orthopedic market and enhancing future growth potential.
- Future Outlook: OrthoPediatrics projects FY25 revenue of $236.1 million, reflecting a positive outlook for future markets, although current profitability issues suggest a need for improvement in earnings management.
- Market Reaction: Despite strong revenue growth, the decline in EPS may lead to negative short-term reactions from the market, prompting investors to monitor future measures for profitability improvement.
OrthoPediatrics and iotaMotion Partner Receive FDA Clearance
- FDA Clearance Expansion: iotaMotion's iotaSOFT® Insertion System has received FDA 510(k) clearance for use in children aged four and older, significantly broadening access to robotic-assisted cochlear implantation and expected to enhance OrthoPediatrics' market share in the pediatric ENT sector.
- Deepening Strategic Partnership: The collaboration between OrthoPediatrics and iotaMotion aims to integrate advanced robotic technology into pediatrics, improving the efficiency and consistency of cochlear implant surgeries, thereby solidifying its leadership position in pediatric healthcare.
- First Adopting Hospital: Cincinnati Children's Hospital becomes the first dedicated pediatric center to adopt the iotaSOFT Insertion System, joining over 35 leading cochlear implant centers in the U.S., marking widespread recognition of this technology in pediatrics and likely encouraging further hospital adoption.
- Broad Market Prospects: OrthoPediatrics plans to leverage this technology to expand its impact in pediatric care, supported by a capital-light business model and diverse revenue streams, addressing unmet pediatric needs effectively.
OrthoPediatrics Corp. Enhances Specialty Bracing Line with Launch of Two New Products
New Product Launches: OrthoPediatrics Corp. has expanded its OrthoPediatrics Specialty Bracing portfolio with the introduction of the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems, aimed at treating Developmental Dysplasia of the Hip (DDH) in children aged three years and younger.
Collaboration with Experts: The new products were developed in collaboration with leading pediatric hip specialists, enhancing treatment options for patients and their families.
Commitment to Pediatric Care: Joe Hauser, President of the Specialty Bracing division, emphasized the company's focus on organic product development and its commitment to improving pediatric orthopedic care through innovative solutions.
Comprehensive Product Offering: Founded in 2006, OrthoPediatrics markets over 85 products across various pediatric orthopedic categories, including trauma, deformity, scoliosis, and sports medicine, serving both the U.S. and international markets.
What Factors Might Influence the OrthoPediatrics Narrative Following Analyst Updates?
Analyst Price Target Changes: OrthoPediatrics' consensus analyst price target has been lowered from $26.29 to $24.14, reflecting a cautious outlook amid mixed research commentary and short-term challenges.
Bullish Analyst Sentiment: Despite the lowered price targets, several firms maintain positive ratings, emphasizing confidence in the company's core business and long-term prospects, particularly in high-margin product lines.
Bearish Analyst Concerns: Some analysts express caution, citing near-term headwinds and lower guidance, with notable reductions in price targets and concerns over revenue visibility impacting future growth expectations.
Company Developments: OrthoPediatrics announced an intangible asset impairment of $2.27 million, received FDA approval for a new system, and revised its 2025 revenue guidance downward, while also reporting improved net profit margins.
Understanding OrthoPediatrics: Key Takeaways from 9 Analyst Evaluations
Analyst Ratings Overview: OrthoPediatrics has received mixed ratings from analysts, with 6 bullish, 3 somewhat bullish, and no bearish ratings in the last 30 days, reflecting a shift in sentiment compared to previous months.
Price Target Adjustments: Analysts have lowered their 12-month price targets for OrthoPediatrics, with an average target now at $27.44, down from $36.44, indicating a decrease in expected stock performance.
Financial Performance Metrics: The company has shown a revenue growth rate of approximately 15.68% and maintains a net margin of -11.64%, outperforming industry standards in terms of financial performance.
Debt Management and Ratios: OrthoPediatrics has a debt-to-equity ratio of 0.27, which is below industry norms, suggesting a solid financial structure and effective management of shareholder equity.
